Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism

Brain Res. 2010 Jul 16:1344:192-9. doi: 10.1016/j.brainres.2010.05.010. Epub 2010 May 12.

Abstract

The present study evaluated the ability of salicylic acid (SA) to attenuate long-term L-DOPA-induced 6-hydroxydopamine (6-OHDA) formation in the striatum of mice, and to protect against the resulting dopaminergic neurotoxicity. The production of 6-OHDA from dopamine in vitro from ferrous-ascorbate-dopamine (FAD) hydroxyl radical ((*)OH) generating system or in vivo in the striatum following prolonged administration of L-DOPA in mice were found to be significantly attenuated by SA. Intra-median forebrain bundle infusion of FAD, but not equivalent dose of ferrous ion or dopamine individually, caused significant striatal dopamine depletion, which was blocked by SA administration. The dose- and time-dependent increase in the formation of 6-OHDA following L-DOPA treatment in the mouse striatum was synergistically enhanced to the systemic administration of the parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. SA treatment significantly attenuated the L-DOPA plus the parkinsonian neurotoxin-induced striatal 6-OHDA generation, and protected against striatal dopamine loss. The present study demonstrated a novel mode of dopaminergic neuroprotection by SA and its possible therapeutic implication in the treatment of Parkinson's disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • 3,4-Dihydroxyphenylacetic Acid / metabolism
  • Animals
  • Corpus Striatum / drug effects
  • Disease Models, Animal
  • Dopamine / metabolism
  • Dopamine Agents / adverse effects*
  • Homovanillic Acid / metabolism
  • Levodopa / adverse effects*
  • Male
  • Medial Forebrain Bundle / drug effects
  • Mice
  • Mice, Inbred BALB C
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Oxidopamine / metabolism*
  • Parkinsonian Disorders / chemically induced
  • Parkinsonian Disorders / drug therapy*
  • Parkinsonian Disorders / pathology
  • Rats
  • Rats, Sprague-Dawley
  • Salicylates / pharmacology
  • Salicylates / therapeutic use*

Substances

  • Dopamine Agents
  • Neuroprotective Agents
  • Salicylates
  • 3,4-Dihydroxyphenylacetic Acid
  • Levodopa
  • Oxidopamine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Dopamine
  • Homovanillic Acid